Editorials

Life without COX 2 inhibitors

BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7553.1287 (Published 01 June 2006) Cite this as: BMJ 2006;332:1287
  1. Allen F Shaughnessy (Allen.Shaughnessy@Tufts.edu), adjunct professor of public health and family medicine,
  2. Andrea E Gordon, clinical assistant professor of public health and family medicine
  1. Tufts University Family Medicine Residency, 100 Hospital Road, Malden, MA 02148, USA
  2. Tufts University Family Medicine Residency, 100 Hospital Road, Malden, MA 02148, USA

    Doctors need to broaden their approach to pain in older patients

    Several cyclo-oxygenase-2 inhibitors (COX 2 inhibitors) have been withdrawn from sale in many countries. The use of other drugs in this class is being limited by their potential to cause cardiac effects. As Kearney and colleagues show (p 1302), this concern is valid, since they have been associated with an increased risk of myocardial infarction with prolonged use as compared with placebo or other non-steroidal anti-inflammatory drugs.1

    Have we lost a truly superior option? Probably not. Although COX 2 inhibitors were marketed as being less likely to cause gastrointestinal distress and ulceration, there is good evidence that other pharmacological and non-drug options may be reasonably effective, equally safe, and less costly.

    COX 2 inhibitors rose to market prominence on the basis of premarketing and postmarketing studies showing less ulceration, on endoscopy, of the gastrointestinal tract. However, ulceration is neither intrinsically harmful nor a surrogate marker for harm associated with use of non-steroidal anti-inflammatory drugs (NSAIDs).2

    Gastroduodenal damage found on endoscopy in clinical …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe